OncoMune, LLC (OncoMune) is a pharmaceutical company engaged in the development of targeted therapeutics for the treatment of cancer. The company is specifically focused on targeting the epigenetic transcription factor BORIS, a protein believed to be one of the ÃƒÆ’Ã‚Â¢ÃƒÂ¢Ã¢â‚¬Å¡Ã‚Â¬Ãƒâ€¦Ã¢â‚¬Å“master switchesÃƒÆ’Ã‚Â¢ÃƒÂ¢Ã¢â‚¬Å¡Ã‚Â¬Ãƒâ€šÃ‚Â in the cancer process. It is into many collaborations with some of the leading pharmaceutical companies to perform various operations so as to cut the need for infrastructure development while allowing flexibility. OncoMune conducts its operations through bioRASI, which is a global contract research organization (CRO) owned by the Vendevia Group. The company is headquartered Hollywood in Florida, the US.